v0.20.4 refine antigravity research skills

2026-05-07 13:43:04 +08:00
parent 4ab502df91
commit a0f1144f6c
14 changed files with 782 additions and 326 deletions
@@ -0,0 +1,157 @@
+---
+name: method-selection
+description: Selects the appropriate research framework and analytical tools for biomedical, market, investment, CMC/GMP, clinical, R&D, BD, and management consulting topics instead of defaulting to MECE or McKinsey-style framing.
+---
+
+# Method Selection
+
+Use this skill before Phase 0-1 framing and whenever the user changes the report purpose.
+
+## Principle
+
+Do not default to McKinsey/MECE. MECE, SCQA, and pyramid writing are useful communication tools, not universal research methods.
+
+Select the method based on:
+
+- report purpose
+- audience
+- decision to support
+- available materials
+- evidence type
+- regulatory or scientific risk
+- output format
+
+## Method Router
+
+### Market, investment, or commercial strategy
+
+Use when the user asks about market opportunity, competition, investment thesis, BD opportunity, pricing, or commercialization.
+
+Methods and tools:
+
+- market sizing: TAM/SAM/SOM, bottom-up demand model, volume-price bridge
+- competitive landscape: segmentation, product differentiation, launch timing, share shifts
+- value chain: upstream supply, manufacturing bottlenecks, channel economics
+- investment: thesis tree, scenario analysis, sensitivity analysis, risk-adjusted NPV where feasible
+- transaction/BD: deal comps, licensing terms, patent cliff, strategic fit
+
+Outputs:
+
+- market map
+- competitor table
+- assumptions ledger
+- upside/base/downside scenarios
+
+### Clinical, translational, or evidence review
+
+Use when the topic is efficacy, safety, trial design, disease area, standard of care, biomarker, or clinical development.
+
+Methods and tools:
+
+- PICO or PICOTS framing
+- evidence hierarchy
+- endpoint and comparator analysis
+- trial design critique
+- TPP and go/no-go criteria
+- benefit-risk assessment
+
+Outputs:
+
+- clinical evidence matrix
+- trial landscape
+- endpoint comparability table
+- evidence gaps and patient-selection risks
+
+### CMC, GMP, quality, or manufacturing operations
+
+Use when the topic involves process development, tech transfer, validation, inspection readiness, deviations, CAPA, sterility assurance, supply chain, or manufacturing risk.
+
+Methods and tools:
+
+- ICH / FDA / EMA / NMPA regulatory baseline mapping
+- gap assessment
+- FMEA or risk matrix
+- process validation lifecycle
+- control strategy mapping
+- deviation/CAPA effectiveness review
+- data integrity assessment
+
+Outputs:
+
+- gap register
+- risk heatmap
+- CAPA prioritization
+- control strategy map
+- readiness scorecard
+
+### R&D feasibility or technology assessment
+
+Use when the topic asks whether a technology, target, modality, platform, assay, or process is feasible.
+
+Methods and tools:
+
+- technology readiness level
+- critical path analysis
+- mechanism and modality fit
+- experiment roadmap
+- scale-up risk assessment
+- IP and freedom-to-operate screening
+
+Outputs:
+
+- feasibility scorecard
+- key experiments
+- kill criteria
+- technical risk register
+
+### Management, organization, or operating model
+
+Use when the topic involves organization, governance, operating cadence, capability building, performance management, or transformation.
+
+Methods and tools:
+
+- issue tree
+- operating model design
+- RACI / decision rights
+- KPI tree
+- process maturity assessment
+- change management roadmap
+
+Outputs:
+
+- operating model options
+- capability gap assessment
+- implementation roadmap
+- KPI and governance model
+
+### Policy, regulation, or access environment
+
+Use when the topic asks about policy, reimbursement, regulatory pathways, pricing access, or regional rules.
+
+Methods and tools:
+
+- policy timeline
+- stakeholder map
+- regulatory pathway comparison
+- access and reimbursement framework
+- scenario analysis by jurisdiction
+
+Outputs:
+
+- jurisdiction comparison
+- policy impact map
+- regulatory milestone table
+- access risks
+
+## Phase 0-1 Output Requirements
+
+Write a method decision note in `phase1/research_brief.md`:
+
+- selected method
+- why it fits
+- methods rejected and why
+- evidence types needed
+- search routes
+- expected output artifacts
+
+If the topic spans multiple scenarios, combine methods explicitly and define which chapters use which method.